JY
SMMT icon

Jeff Yass’s Summit Therapeutics SMMT Stock Holding History

Jeff Yass’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.6M Sell
521,339
-82,594
-14% -$1.46M ﹤0.01% 3847
2026
Q1 		$11.5M Buy
+603,933
New +$9.77M ﹤0.01% 2909
2025
Q4 		– Sell
-246,562
Closed -$4.64M – 13521
2025
Q3 		$5.09M Sell
246,562
-53,411
-18% -$1.3M ﹤0.01% 4070
2025
Q2 		$6.38M Buy
299,973
+46,474
+18% +$1.06M ﹤0.01% 3537
2025
Q1 		$4.89M Buy
253,499
+176,275
+228% +$3.54M ﹤0.01% 3697
2024
Q4 		$1.38M Sell
77,224
-289,171
-79% -$5.61M ﹤0.01% 6158
2024
Q3 		$8.02M Buy
366,395
+112,594
+44% +$1.57M ﹤0.01% 2921
2024
Q2 		$1.98M Buy
253,801
+92,463
+57% +$499K ﹤0.01% 5118
2024
Q1 		$668K Sell
161,338
-69,012
-30% -$274K ﹤0.01% 7805
2023
Q4 		$601K Buy
230,350
+103,979
+82% +$214K ﹤0.01% 8210
2023
Q3 		$236K Sell
126,371
-252,971
-67% -$482K ﹤0.01% 9857
2023
Q2 		$952K Sell
379,342
-1,309,223
-78% -$2.39M ﹤0.01% 6788
2023
Q1 		$2.95M Buy
1,688,565
+1,408,141
+502% +$3.84M ﹤0.01% 4358
2022
Q4 		$1.19M Buy
280,424
+198,717
+243% +$361K ﹤0.01% 5801
2022
Q3 		$97K Buy
81,707
+58,070
+246% +$65.7K ﹤0.01% 11734
2022
Q2 		$24K Buy
+23,637
New +$33.1K ﹤0.01% 12315
2022
Q1 		– Sell
-14,461
Closed -$39K – 13896
2021
Q4 		$39K Buy
14,461
+1,641
+13% +$7.89K ﹤0.01% 12667
2021
Q3 		$64K Buy
+12,820
New +$92K ﹤0.01% 12263
2021
Q2 		– Sell
-133,808
Closed -$878K – 13208
2021
Q1 		$785K Buy
133,808
+105,922
+380% +$683K ﹤0.01% 8355
2020
Q4 		$131K Buy
+27,886
New +$118K ﹤0.01% 10344
2019
Q4 		– Sell
-26,491
Closed -$47K – 10558
2019
Q3 		$47K Buy
+26,491
New +$35.8K ﹤0.01% 9794
2019
Q1 		– Sell
-10,569
Closed -$12K – 9761
2018
Q4 		$12K Buy
+10,569
New +$16.4K ﹤0.01% 8733
2017
Q4 		– Sell
-146,000
Closed -$1.83M – 9854
2017
Q3 		$1.83M Buy
+146,000
New +$1.89M ﹤0.01% 4081

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jeff Yass's SMMT Position: Q2 2026 in Review

Jeff Yass reduced its Summit Therapeutics (SMMT) stake by 14% in Q2 2026, selling an estimated $1.46M and leaving 521,339 shares worth $7.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3847.

Jeff Yass first reported a position in SMMT in Q3 2017 and has held it in 23 quarters since. The position peaked at $11.5M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Jeff Yass held 521,339 shares of Summit Therapeutics worth $7.6M as of Q2 2026.
  • Jeff Yass sold 82,594 Summit Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Summit Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3847 holding.
  • Jeff Yass first reported a position in Summit Therapeutics in Q3 2017 and has held it in 23 quarters since.
  • Jeff Yass's Summit Therapeutics position peaked at $11.5M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.